ABANZA Strengthens U.S. Commercial Leadership with Appointment of Tim Kunkel as Vice President of Sales
Source: PR NewswireView original on PR Newswire
ORLANDO, Fla., Nov. 17, 2026 /PRNewswire/ -- ABANZA, an innovative medical device company focused on advancing soft tissue fixation, is pleased to announce the appointment of Tim Kunkel as Vice President of Sales, further strengthening its U.S. commercial organization as the company accelerates its growth in the sports medicine and soft tissue repair markets.
Kunkel brings extensive experience in the orthopedic medical device industry, with a strong background in commercial strategy, sales leadership, and market development. Throughout his career, he has worked with innovative medical technology companies, helping introduce new technologies, develop commercial strategies, and expand market adoption.
Prior to joining ABANZA, Kunkel held senior commercial leadership positions at Miach Orthopaedics and Rotation Medical. His extensive experience in the sports medicine sector and his proven ability to bring innovative orthopedic technologies to market will be valuable as ABANZA enters its next phase of growth.
"Tim brings exactly the kind of experience and industry knowledge we need as we continue expanding our presence in the U.S. market," said Juan Abascal, Founder and CEO of ABANZA. "His commercial expertise, relationships across the orthopedic industry, and experience with innovative sports medicine technologies will be instrumental in strengthening our sales organization and accelerating the adoption of our Soft Tissue Fixation Platform."
In his new role, Kunkel will lead ABANZA's U.S. sales strategy, focusing on expanding its distribution network, strengthening relationships with surgeons and commercial partners, and driving adoption of the company's growing product portfolio.
"I'm excited to join ABANZA at such an important stage of its growth," said Tim Kunkel, Vice President of Sales at ABANZA. "The company has developed a truly innovative approach to soft tissue fixation, and I see tremendous potential for its technology in the U.S. market. I look forward to working with the team to expand our commercial presence and bring these solutions to more surgeons and patients."
ABANZA's Soft Tissue Fixation Platform, including its FDA-cleared WasherCap™, WasherCap™ Mini, and QuadLock™ technologies, has been developed to address unmet needs in orthopedic soft tissue repair. Initially focused on knee procedures, the company is expanding its technology into additional applications, including foot and ankle, hand and wrist, hip, and shoulder surgery.
About ABANZA
ABANZA is an innovative medical device company specializing in the development of advanced solutions for orthopedic soft tissue fixation. Through its proprietary Soft Tissue Fixation Platform, the company aims to provide surgeons with simpler, more versatile, and effective technologies that address unmet clinical needs. With a growing portfolio of FDA-cleared products and a commitment to continuous innovation, ABANZA is driving A New Era in Soft Tissue Fixation.
For more information, visit www.abanzamed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/abanza-strengthens-us-commercial-leadership-with-appointment-of-tim-kunkel-as-vice-president-of-sales-302942280.html
Source: PR NewswireView original on PR Newswire
Content provided by PR Newswire. Redistribution, resale or sublicensing is not permitted.